TD Cowen Maintains Buy on Jersey Mike's Subs, Lowers Price Target to $22
TD Cowen analyst Andrew M. Charles maintains Jersey Mike's Subs (NYSE:JMKE) with a Buy and lowers the price target from $26 to $22.
Stocks · News reference
Jersey Mike's Subs began trading Friday on the NYSE after pricing its IPO at $23 per share, valuing the chain at $1 billion.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
TD Cowen analyst Andrew M. Charles maintains Jersey Mike's Subs (NYSE:JMKE) with a Buy and lowers the price target from $26 to $22.
Filed: 2026-09-22 AccNo: 0001193125-26-397249 Size: 152 KB Item 5.01: Changes in Control of Registrant Item 8.01: Other Events
SRX Global Inc. announced a definitive agreement to acquire CERo Therapeutics Holdings, Inc., an innovative cellular immunotherapy company developing CER-1236 for hematologic malignancies. The acquisition will be structured through a wholly-owned SPV (CERO 1236) to avoid diluting existing SRX shareholders. The transaction is expected to accelerate CER-1236's clinical development and provide CERo with enhanced access to capital and operational resources. CERo has treated six patients in its Phase 1 CERTAIN-T trial with no dose-limiting toxicities observed at increased dose levels.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1471727/000149315226046085/form8-k.htm